A national randomised multi-centre trial to assess the effect of oral magnesium supplementation on the kinetics of magnesium wasting induced by EGFR targeted antibody therapy for colorectal carcinoma (the MAGNET trial). - MAGNET

Belgian Group of Digestive Oncology0 个研究点开始时间: 2007年4月17日最近更新: 2017年8月21日

适应症

试验速览

暂无简介。

•1.Subjects with colorectal cancer in whom treatment with anti-EGFR targeted antibodies is being started in the metastatic or adjuvant setting.
•2.Subjects must provide written witnessed informed consent prior to any study procedures being performed
•3.Male or female subjects aged between 18 and 80 years
•4.Subjects must be able to understand the study, comply with the study requirements and return to the investigational site for assessments at specified times
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1.Subjects treated with cisplatin based chemotherapy within 6 months prior to inclusion
•2.Subjects with renal failure, i.e. creatinine levels > 2 mg/dl or creatinine clearance < 50 mg/dl
•3.Subjects with baseline hypomagnesemia
•4.Subjects with baseline diarrhea, i.e. > 4 bowel movements/day
•5.Subjects with known intolerance to magnesium supplementation
•6.Subjects with short bowel
•7.Subjects with known or impending bowel obstruction

发起方